中国科技核心期刊
CN:31-1600/Q
ISSN:1004-0374
“健康与疾病的免疫”国际学术研讨会通知      关于有网站冒充本刊网站的声明
《生命科学》 2014, 26(9): 943-948
基于血凝素(HA)的新型流感疫苗研究进展
王 祥,周东明*
(中国科学院上海巴斯德研究所疫苗研究中心,上海 200031)
新型广谱流感疫苗是预防和控制不断变异的流感病毒的重要手段。血凝素(HA) 是流感病毒表面
    的糖蛋白,具有免疫原性,但其变异性强,是A 型流感病毒发生抗原变异的主要原因。近年来研究发现,HA 存在保守的恒定区,可诱导机体产生流感病毒特异性广谱中和抗体,拮抗多种流感病毒的感染。因此,如何采取不同策略和方法,研发基于HA 的新型疫苗成为流感防治研究的重点。就基于HA 的新型流感疫苗研究进展作一综述。
 
Advances in the development of novel influenza vaccines based on hemagglutinin
WANG Xiang, ZHOU Dong-Ming*
(Vaccine Research Center of Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China)
Novel universal influenza vaccine has been considered to be the most economic and effective way to prevent from the emerging influenza virus with unpredictable mutation. Hemagglutinin (HA) is an influenza virus surface glycoprotein with high immunogenicity and antigenic variability. Recently, conserved domains in HA have been identified, and they can induce broadly neutralizing antibodies against heterotype influenza infection in the host. So, generation of HA-based novel influenza vaccines by using various strategies became a hot topic in prevention and control of influenza infection. Here, advances in the development of novel influenza vaccine based on HA are summarized.
 
首页 | 刊物简介 | 编委会 | 投稿须知 | 广告业务 | 过刊浏览 | 联系我们
中国科学院上海生命科学信息中心《生命科学》编辑部
Copyright © 2012-2015 《生命科学》编辑部 All Rights Reserved.
沪ICP备05033115号-30
您是第2878486 位访问者,欢迎!